Drug Trial Radar · NCT04206163
Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis
Last checked: Nov 20, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jan 20, 2020
Primary completion
Jun 24, 2024
Study completion Jun 24, 2024
Sponsor
- Lead sponsor
- Vastra Gotaland RegionGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Dec 20, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective imaging study investigates the diagnostic ability of Gallium-68 DOTA-TOC (68Ga-DOTA-TOC) positron emission tomography/computed tomography (PET/CT) in the clinical work-up of patients with 1) clinically suspected acute myocarditis (n=30-40) and 2) clinically suspected cardiac sarcoidosis (n=30-40) using clinical diagnostic criteria as well as endomyocardial biopsy as reference. Furthermore, 68Ga-DOTA-TOC PET/CT findings will be compared with results from contrast-enhanced magnetic resonance imaging (MRI) and in case of cardiac sarcoidosis even Fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT, which are both performed as part of the clinical routine work-up.
Conditions
- Acute Myocarditis
- Cardiac Sarcoidosis
Interventions
68Ga-DOTA-TOC PET/CTDiagnostic test
Somatostatin receptor imaging
Blood sampleBiological
Analysis of inflammatory biomarkers
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI in patients with clinically suspected acute myocarditis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)Time frame: Completion of enrollment, approximately 2 years
- Specificity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI in patients with clinically suspected acute myocarditis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)Time frame: Completion of enrollment, approximately 2 years
- Sensitivity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI and 18F-FDG PET/CT in patients with clinically suspected cardiac sarcoidosis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)Time frame: Completion of enrollment, approximately 5 years
- Specificity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI and 18F-FDG PET/CT in patients with clinically suspected cardiac sarcoidosis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)Time frame: Completion of enrollment, approximately 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sahlgrenska University Hospital
Gothenburg, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.